# Polygenic risk score-based phenome-wide association study identifies novel associations for Tourette syndrome

Pritesh Jain, Tyne Miller-Fleming, Apostolia Topaloudi, Dongmei Yu, Petros Drineas, Marianthi Georgitsi, Zhiyu Yang, Renata Rizzo, Kirsten R Müller-Vahl, Zeynep Tumer, et al.

► To cite this version:

Pritesh Jain, Tyne Miller-Fleming, Apostolia Topaloudi, Dongmei Yu, Petros Drineas, et al. Polygenic risk score-based phenome-wide association study identifies novel associations for Tourette syndrome. *Translational Psychiatry*, 2023, 13, 10.1038/s41398-023-02341-5 hal-04529833

HAL Id: hal-04529833

https://hal.sorbonne-universite.fr/hal-04529833

Submitted on 2 Apr 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
ARTICLE **OPEN**

<figure><img src="image_2.png" /></figure>

Check for updates

# Polygenic risk score-based phenome-wide association study identifies novel associations for Tourette syndrome

Pritesh Jain¹, Tyne Miller-Fleming²,³, Apostolia Topaloudi¹, Dongmei Yu⁴,⁵, Petros Drineas⁶, Marianthi Georgitsi⁷,⁸, Zhiyu Yang¹, Renata Rizzo⁹, Kirsten R. Müller-Vahl ID¹⁰, Zeynep Tumer ID¹¹,¹², Nanette Mol Debes¹³, Andreas Hartmann¹⁴, Christel Depienne ID¹⁵, Yulia Worbe¹⁶,¹⁷, Pablo Mir ID¹⁸,¹⁹, Danielle C. Cath²⁰, Dorret I. Boomsma ID²¹,²², Veit Roessner ID²³, Tomasz Wolanczyk²⁴, Piotr Janik²⁵, Natalia Szejko²⁵,²⁶, Cezary Zekanowski ID²⁷, Csaba Barta ID²⁸, Zsofia Nemoda ID²⁸, Zsanett Tarnok ID²⁹, Joseph D. Buxbaum ID³⁰,³¹,³²,³³,³⁴,³⁵, Dorothy Grice³⁰,³⁴,³⁵,³⁶, Jeffrey Glennon³⁷, Hreinn Stefansson³⁸, Bastian Hengerer ID³⁹, Noa Benaroya-Milshtein⁴⁰, Francesco Cardona⁴¹, Tammy Hedderly ID⁴², Isobel Heyman⁴³, Chaim Huyser ID⁴⁴,⁴⁵, Astrid Morer⁴⁶,⁴⁷,⁴⁸, Norbert Mueller⁴⁹, Alexander Munchau⁵⁰, Kerstin J. Plessen⁵¹,⁵², Cesare Porcelli⁵³, Susanne Walitza⁵⁴, Anette Schrag⁵⁵, Davide Martino⁵⁶, The Psychiatric Genomics Consortium Tourette Syndrome Working Group (PGC-TS), The EMTICS collaborative group, Andrea Dietrich⁵⁷, The TS-EUROTRAIN Network, Carol A. Mathews ID⁵⁸, Jeremiah M. Scharf⁴,⁵,⁵⁹, Pieter J. Hoekstra⁵⁷, Lea K. Davis²,³¤ and Peristera Paschou¹¤

© The Author(s) 2023

Tourette Syndrome (TS) is a complex neurodevelopmental disorder characterized by vocal and motor tics lasting more than a year. It is highly polygenic in nature with both rare and common previously associated variants. Epidemiological studies have shown TS to be correlated with other phenotypes, but large-scale phenome wide analyses in biobank level data have not been performed to date. In this study, we used the summary statistics from the latest meta-analysis of TS to calculate the polygenic risk score (PRS) of individuals in the UK Biobank data and applied a Phenome Wide Association Study (PheWAS) approach to determine the association of disease risk with a wide range of phenotypes. A total of 57 traits were found to be significantly associated with TS polygenic risk, including multiple psychosocial factors and mental health conditions such as anxiety disorder and depression. Additional associations were observed with complex non-psychiatric disorders such as Type 2 diabetes, heart palpitations, and respiratory conditions. Cross-disorder comparisons of phenotypic associations with genetic risk for other childhood-onset disorders (e.g.: attention deficit hyperactivity disorder [ADHD], autism spectrum disorder [ASD], and obsessive-compulsive disorder [OCD]) indicated an overlap in associations between TS and these disorders. ADHD and ASD had a similar direction of effect with TS while OCD had an opposite direction of effect for all traits except mental health factors. Sex-specific PheWAS analysis identified differences in the associations with TS genetic risk between males and females. Type 2 diabetes and heart palpitations were significantly associated with TS risk in males but not in females, whereas diseases of the respiratory system were associated with TS risk in females but not in males. This analysis provides further evidence of shared genetic and phenotypic architecture of different complex disorders.

*Translational Psychiatry* (2023)13:69; https://doi.org/10.1038/s41398-023-02341-5

## INTRODUCTION

Tourette Syndrome (TS) is a complex neurodevelopmental disorder characterized by vocal and motor tics lasting more than a year [1]. It is a childhood-onset condition with a prevalence of 0.6–0.8% in school age children and has a population heritability of 70% and SNP-based heritability estimates ranging from 0.21 to 0.58 [2–6]. TS is highly polygenic in nature and multiple genetic variants account for a substantial proportion of phenotypic variance of the condition [6–11].

Epidemiological studies have shown TS to be associated with various phenotypes and disorders, but large-scale phenome-wide analyses in biobank level data have not been performed to date [12, 13]. This is likely due to the scarcity of individuals with TS in biobank-scale available datasets. To address this, polygenic risk

scores (PRS), a measure of an individual's genetic predisposition for a disease, can be used as a proxy for the case-control status of TS [14]. Such scores can be used to identify different general health, mental health, and socio-demographic outcomes associated with the genetic risk of a disorder. They may also help to identify other phenotypes associated with TS genetic risk and explore causal relationships between TS and other phenotypes [15].

PRS-based phenome-wide association studies (PheWAS) have become an increasingly common method to identify different factors associated with the genetic risk of a complex disease [16–19]. Since the scores are calculated based on genomic information that is fixed at birth, this method has the advantage of being less susceptible to reverse causality [15]. Applying PRS based PheWAS methods across large datasets like the UK Biobank
has led to the identification of novel phenotypes associated with genetic risk of psychiatric disorders that have been previously correlated with TS [20, 21], such as autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia and major depressive disorder [22]. These associations have also shed light on the shared genotypic architecture of such related disorders.

Here, using the summary statistics from the latest GWAS meta-analysis of TS [11] and genomic and phenomic data from the UK Biobank (UKB), we conducted a PRS-based PheWAS for TS, interrogating a wide range of phenotypes including physical and mental health, biochemical, and socio-demographic factors. Our goal was to uncover phenotypes that may be associated with TS genetic risk and compare to phenotypic associations with genetic risk of other disorders along the impulsivity-compulsivity spectrum that have previously been found to be genetically associated with TS [20, 21]. This work furthers our knowledge on the TS phenotype and genetic architecture and can serve as a basis for future analysis that will investigate potentially causal relationships between the phenotypes that are found associated with TS genetic risk.

# METHODS

## Study population and quality control

The UK Biobank dataset (Application Number 61553) which has data from ~500,000 individuals was used for the PheWAS analysis. All appropriate patient/participant consent has been obtained and the appropriate institutional forms have been archived. We removed individuals with non-white British ancestry based on the self-reported ancestry information available in the UK Biobank data. Next, we removed individuals with greater than third degree relatedness based on the kinship coefficient. Finally, we ran principal component analysis using TeraPCA [23] to remove individuals who did not overlap with European samples in the 1000 Genomes dataset (mean PC value of top 6 PCs ± 3 SD). We ran further quality controls on the genotype data to remove individuals with missingness >0.02, SNPs with missingness >0.02, minor allele frequency <0.01 and Hardy-Weinberg threshold of 1e-06, resulting in a dataset of 330841 participants used for the analyses.

## PRS calculation

PRScs software was used for the calculation of PRS [24]. This method utilizes a Bayesian regression framework and places a continuous shrinkage prior on the variant effect sizes using GWAS summary data and an external linkage disequilibrium (LD) panel. We used the 1000 Genomes European LD reference with HapMap3 SNPs, to update effect sizes jointly for all the SNPs in LD. The output is a file with updated effect size estimates which we used to calculate PRS using the score function in Plink. The summary statistics file required for the estimation of risk scores was obtained from the latest GWAS meta-analysis of TS [11] with 6,133 cases and 13,565 controls to compute a weighted, mean score for each individual separately. The GWAS for other disorders were obtained from the Psychiatric Genomics Consortium [25–27] and the number of SNPs used for PRS calculation are mentioned in the Supplementary Table 1.

## Phenome wide association study

PHESANT package was used to run the PheWAS [28]. This tool was designed specifically to study the associations in UKB data. It classifies each phenotype as one of four data types: continuous, binary, ordered categorical, or unordered categorical and then estimates the association between PRS scores and each phenotype using a regression model that fits the data type of the phenotype (linear, logistic-binary, ordered-logistic, or multinomial-logistic). We included 2242 phenotypes which were classified into 50 UKB categories and were manually grouped into five categories in our analysis (biochemical markers, cognition and mental health, disease diagnosis, health and medical history, socio-demographics). The phenotypes in the disease diagnosis category were obtained after mapping the 17,000 ICD-10 diagnosis codes of the UKB to 1430 phenotypic codes using the Natural Language Processing (NLP) method implemented in the R package Phewas [29]. The number of phenotypes in each category are shown in Table 1 and the sub-categories are shown in Fig. 1 and

<table><caption>**Table 1.** Total number of phenotypes analyzed by category.</caption><thead><tr><td>Categories</td><td>Total number</td></tr></thead><tbody><tr><td>Biochemical Measures</td><td>167</td></tr><tr><td>Cognition and Mental Health</td><td>223</td></tr><tr><td>Disease Diagnoses</td><td>1430</td></tr><tr><td>Health and Medical History</td><td>270</td></tr><tr><td>Sociodemographics</td><td>152</td></tr></tbody></table>

Supplementary Table 2. Age, sex, and genotyping batch derived from the UKB data and top 10 PCs calculated using TeraPCA were used as covariates for the analysis. To account for multiple testing, we used a Bonferroni threshold of $p < 2.3 \times 10^{-5}$ (0.05/2242) for the results of our main analyses. Given the possible correlation between various phenotypes, a Bonferroni threshold could be considered to be overly conservative, so we also used a false discovery rate of 0.05 adjusted threshold ($p < 0.00495$) to identify additional phenotypes associated with TS PRS in a secondary analysis. For the sex-specific PheWAS analysis, we split the data into two parts (179976 females and 153440 males) based on the sex data provided in UKB and ran the analyses independently for both datasets.

# RESULTS

## Phenotypes associated with TS

The study included 330,841 unrelated individuals from the UKB dataset that were selected after filtering out individuals with non-European ancestry and other quality control measures. We tested the association of the scores with 2,242 phenotypes grouped into five major categories.

The overall results of our TS PRS-PheWAS are shown in Fig. 2 and additional file 1. The analysis identified 57 outcomes significantly associated with TS PRS after Bonferroni correction for multiple testing ($p < 2.23 \times 10^{-5}$) (Fig. 3 and Supplementary Table 3a-e). The variable "Seen doctor for nerves, anxiety or depression" had the strongest association with TS PRS (beta: 0.031, $p$-value: $9.2 \times 10^{-17}$). Twenty other cognition and mental health phenotypes were also observed to be significantly associated with TS PRS, with all of them having a positive association at the significant thresholds. This included associations for psychosocial factors like neuroticism score (beta: 0.026, $p$-value: $2.87 \times 10^{-15}$), "worrier or anxious feelings" (beta: 0.026, $p$-value: $8.2 \times 10^{-13}$), and the "tense/highly strung" trait (beta: 0.034, $p$-value: $4.28 \times 10^{-13}$). Various other behavioral traits were also found to be positively associated with TS PRS, including "increased mood swings" (beta: 0.019, $p$-value: $9.8 \times 10^{-8}$), higher chance of "feeling miserable" (beta: 0.017, $p$-value: $9.32 \times 10^{-6}$), and higher chance of "feeling unenthusiastic/disinterested for a whole week" (beta: 0.036, $p$-value: $3.05 \times 10^{-8}$). We also observed that higher TS genetic risk was associated with "higher chances of being physically abused by family as child" (beta: 0.038, $p$-value: $1.57 \times 10^{-6}$).

Within the disease diagnosis category, we found eight outcomes significantly associated with TS risk scores with strong associations observed for psychiatric conditions including depressive episode (beta: 0.051, $p$-value: $2.38 \times 10^{-11}$) and anxiety disorder (beta: 0.037, $p$-value: $6.9 \times 10^{-6}$). We also observed non-mental health related diseases to be significantly associated with TS risk such as peripheral enthesopathies (beta: 0.052, $p$-value: $8.7 \times 10^{-6}$), type 2 diabetes (beta: 0.028, $p$-value: $2.1 \times 10^{-5}$), heart palpitations (beta: 0.063, $p$-value: $1.4 \times 10^{-5}$), and diseases of the respiratory system (beta: 0.045, $p$-value: $1.2 \times 10^{-5} - 2.5 \times 10^{-5}$).

Fourteen health and medical history outcomes were observed to be significantly associated with TS risk, including several pain related phenotypes such as: back pain (beta: 0.027, $p$-value: $2.65 \times 10^{-11}$), neck or shoulder pain (beta: 0.026, $p$-value: $3.54 \times 10^{-10}$), and hip pain (beta: 0.025, $p$-value: $8.9 \times 10^{-6}$). Other significant associations in this category included sensitive stomach (beta: 0.036, $p$-value: $1.3 \times 10^{-6}$), shortness of breath walking on
<figure><img src="image_3.png" /><figcaption>**Fig. 1** Overview of the phenotypic categories in UK Biobank. The size of pie chart sections indicating the number of included outcomes: biochemical measures (167), cognition and mental health (223), disease diagnosis (1430), health and medical history (270) and sociodemographics (152).</figcaption></figure>

<figure><img src="image_4.png" /><figcaption>**Fig. 2** PheWAS Manhattan plot showing associations of phenotypes with TS PRS, grouped by categories. The horizontal line is marked at the Bonferroni threshold of significance for multiple testing ($p < 2.23 \times 10^{-5}$). The top 3 significant associations in each category are highlighted and labeled.</figcaption></figure>

level ground (beta: 0.049, *p*-value: 1.1 × 10<sup>-6</sup>), and mouth ulcers (beta: 0.025 *p*-value: 1.17 × 10<sup>-5</sup>). We also observed that individuals with a higher TS PRS had an increase in overall health rating (beta: 0.019, *p*-value: 2.35 × 10<sup>-8</sup>), indicating poorer overall self-reported health (as defined by UKB) correlated with a higher genetic risk of TS.

Among sociodemographic outcomes, 13 phenotypes were significantly associated with TS PRS, including parameters such as the index of multiple deprivation (beta: 0.008, *p*-value: 1.5 × 10<sup>-5</sup>), education score (beta: 0.012, *p*-value: 8.9 × 10<sup>-11</sup>), and employment score (beta: 0.01, *p*-value: 6.8 × 10<sup>-8</sup>). These results indicate that people with a higher TS PRS in the UKB data had a higher deprivation index and lower levels of education and employment. This was also highlighted by the negative association between TS PRS and the chance of having

a college degree (beta: -0.029, *p*-value: 5.8 × 10<sup>-15</sup>) or an A-level/AS-level qualification (beta: -0.021, *p*-value: 9 × 10<sup>-8</sup>). Finally, we also observed that people with a higher TS PRS had a lower age of first live birth (beta: -0.014, *p*-value: 1.3 × 10<sup>-7</sup>) and also completed their full-time education earlier (beta: -0.029, *p*-value: 1.5 × 10<sup>-13</sup>). Finally, in the biochemical measures category, glycated hemoglobin was found to have a positive association with TS PRS (beta: 0.007, *p*-value: 3 × 10<sup>-6</sup>).

156 phenotypes were found to be significantly associated with TS PRS in our secondary analysis after FDR correction for multiple testing (Supplementary Fig. 1). These included five biochemical measures, 41 cognition and mental health traits, 43 health and medical history outcomes, 25 socio-demographic measures, and 42 phenotypes from the disease diagnosis category. Some of the associations observed included complex
<figure><img src="image_5.png" /><figcaption>**Fig. 3** Forest plot showing phenotypes significantly associated with TS PRS, grouped by categories. The x-axis shows the (Beta) effect size for each phenotype estimated by PheWAS. BM Biochemical Measures.</figcaption></figure>

medical conditions such as asthma, gastroesophageal reflux disease, irritable bowel syndrome, and hypercholesterolemia (beta: 0.02–0.035, *p*-value: $4.6 \times 10^{-3}$— $5.5 \times 10^{-4}$). We also found fluid intelligence scores to be negatively associated with

TS PRS (beta: −0.017, *p*-value: $3.7 \times 10^{-3}$). Biochemical measures such as IGF1 and eosinophil count were also negatively associated with the risk of TS (beta: −0.005 to −0.008, *p*-value: $3.5 \times 10^{-3}$—$3.8 \times 10^{-5}$).
## Comparison across neurodevelopmental disorders

We next proceeded to explore whether phenotypes associated with TS genetic risk were also associated with the genetic risk of other neurodevelopmental disorders that are known to be comorbid with TS, including ADHD, ASD, and OCD. The PRS scores of these disorders were weakly correlated with TS PRS (R²: 0.001–0.11). The PheWAS analysis was repeated for these disorders (additional file 2: Tables 1–3), and we compared the identified associations with TS following Bonferroni correction (Fig. 4 and Table 2). For ADHD, we observed a total of 649 phenotypes significantly associated with ADHD PRS after correction for multiple testing, 53 of which were also found to be significantly associated with TS PRS. We observed that the phenotypic associations overlapping between ADHD and TS had stronger *p*-values and larger effect sizes in the same direction in relation to ADHD PRS compared to TS PRS. A total of 202 phenotypes were significantly associated with ASD PRS, and 34 of them were overlapping with TS phenotype associations. We observed that ASD PRS had a positive association with education-related phenotypes such as college qualifications (beta: 0.067, *p*-value: 5.1 × 10⁻⁶⁹) and A/AS level qualifications (beta: 0.051, *p*-value: 3.6 × 10⁻³⁷), which was contrary to what we found for TS PRS (which had a negative association). This suggests that people with higher genetic risk of ASD had an increased chance of completing college or school education. Among the 99 phenotypes significantly associated with the genetic risk of OCD, we observed that 26 overlapped with those associated with TS PRS. Similar to ASD, we found that education-related phenotypes had a positive association with OCD PRS, again contrary to that seen with TS genetic risk. Additionally, this opposite direction of an association between OCD and TS was seen for all other phenotypes except for cognition and mental health traits. These included association with diseases such as Type 2 diabetes which had a positive association with TS and negative association with OCD risk, pain-related phenotypes, as well as indices of multiple deprivation such as the health score, education score, and employment scores. The associations between deprivation indices and OCD indicate that people with higher OCD PRS have lower deprivation scores in terms of health (beta: −0.012, *p*-value: 2 × 10⁻¹¹), education (beta: −0.018, *p*-value: 1.7 × 10⁻²³), and employment (beta: −0.013, *p*-value: 3.7 × 10⁻¹³).

Sixteen phenotypes were significantly associated with the genetic risk of all four disorders. Almost all of the cognition and mental health traits had similar directions of effect for the four disorders. Type 2 diabetes was significantly associated with all four disorders but was found to be positively associated with TS, ADHD, and ASD, but negatively associated with OCD. Overall, we observed a great degree of overlap between associations observed for TS and the different neurodevelopmental disorders.

## Sex-specific differences

To understand whether there were any differences in the associations between TS and the different phenotypes based on the sex of the individual, we subsequently performed sex-specific PheWAS analysis (additional file 3: Tables 1, 2). Figure 5 shows phenotypes significantly associated with TS PRS in males and females. Among females, we found 15 associations significantly associated with TS PRS, with the strongest association observed for college qualification (beta: −0.033, *p*-value: 1.7 × 10⁻¹⁰) (Supplementary Table 4). In males, we observed 18 associations significantly associated with TS genetic risk, with strong associations observed with mental health traits such as the “tense/highly strung” phenotype (beta: 0.047, *p*-value: 2.8 × 10⁻¹⁰) and neuroticism score (beta: 0.029, *p*-value: 5.3 × 10⁻⁹) (Supplementary Table 5). Although the direction of effect was similar, we observed a difference in the significance and strength of the association with various phenotypes. Overall, eight phenotypes were significantly associated with TS risk in both males and females, and these included socio-demographic traits and a few mental health

outcomes. Notably, we observed that in the disease diagnosis category, only depression was significantly associated with TS risk in both sexes. In males, we observed significant associations with type 2 diabetes (beta: 0.038, *p*-value: 2 × 10⁻⁵) and palpitations (beta: 0.12, *p*-value: 1.4 × 10⁻⁶), both of which were not significantly associated in the PheWAS in females (*p*-value > 0.05). Inversely, we also found that respiratory system diseases were significantly associated with TS genetic risk in females (beta: 0.061, *p*-value: 2.5 × 10⁻⁶) but not in males.

## DISCUSSION

We conducted a PRS-based PheWAS analysis to understand and identify associations between genetic liability for Tourette syndrome and 2242 phenotypes available in the UK Biobank dataset. Significant associations were observed with multiple general health, mental health, and sociodemographic traits. The strongest associations were found between TS PRS and mental health factors. Several associations with complex medical diseases were also observed, including associations with metabolic and respiratory disorders. Cross-disorder comparisons indicated that there was considerable overlap of phenotypes associated with the genetic risk of TS, ADHD, and ASD. Interestingly, OCD PRS had associations with a number of these same phenotypes albeit with an opposite direction of effect. Finally, sex-specific PheWAS analysis highlighted difference in associations of complex disorders with TS PRS in males and females.

We were able to confirm previously observed associations of various phenotypes with TS, including neuroticism [30], anxiety [4], depression [31], and lower educational attainment [32]. The association we observed between TS genetic risk and pain-related phenotypes was also previously observed in a prospective cohort study that investigated pain secondary to tics [33]. Additionally, epidemiological studies have also found a higher prevalence of type 2 diabetes and cardiovascular diseases among individuals with TS, in line with what we observed in our study, indicating that there might be some common biological mechanism between these disorders [12]. We found novel associations of TS genetic risk with various other mental health traits such as mood swings, irritability, nervous feelings, and loneliness that have shown to be associated with the genetic liability as well as clinical presentation of psychiatric disorders such as depression [34]. Interestingly we observed that higher genetic risk of TS was associated with lower maternal age of first live birth, which was also observed in epidemiological studies of ADHD [35].

The results we obtained for the ADHD and ASD PheWAS were also consistent with previous phenome wide association studies for these disorders and we identified additional significant associations [18]. We observed that ASD and OCD had positive associations with school and college education, which has also been reported in genetic correlation analysis between these disorders and educational attainment [30]. This was also valid for the length of education, which had positive correlation with ASD and OCD, and negative correlation with TS and ADHD as seen both in the present and previous studies [30]. These results suggest that although these disorders are highly comorbid with TS and have strong genetic overlap, there are still considerable differences.

We also observed a difference in the association of outcomes with TS PRS based on the sex of the individuals. TS is more common in males than females and there are also differences in the associated phenotypes observed in each group [36–38]. We found differences primarily in associations with disorders such as type 2 diabetes and respiratory conditions, although no difference was observed in the overall PRS score distributions among the sexes. This suggests that there might be sex-chromosome differences or environmental factors influencing these dimorphisms [39].
<figure><img src="image_6.png" /><figcaption>**Fig. 4** Cross-disorder comparison of significant associations with TS and at least one other disorder; asterisk (*) indicates significant association after multiple testing correction. Each column indicates the association between the phenotype and a disorder and the color represents the Beta (effect size) of association between the genetic risk of the disorder and the phenotypes. BM Biochemical Measures.</figcaption></figure>
<table><caption>**Table 2.** Number of significant associations observed for the genetic risk of different neurodevelopmental disorders.</caption><thead><tr><th>Categories</th><th>Significant associations with TS PRS</th><th>Significant associations with ADHD PRS</th><th>Significant associations with ASD PRS</th><th>Significant associations with OCD PRS</th></tr></thead><tbody><tr><td>Biochemical Measures</td><td>1</td><td>35</td><td>18</td><td>23</td></tr><tr><td>Cognition and Mental Health</td><td>21</td><td>120</td><td>93</td><td>26</td></tr><tr><td>Disease Diagnosis</td><td>8</td><td>267</td><td>4</td><td>9</td></tr><tr><td>Health and Medical History</td><td>14</td><td>135</td><td>45</td><td>17</td></tr><tr><td>Sociodemographics</td><td>13</td><td>92</td><td>42</td><td>24</td></tr></tbody></table>

The first column shows the different categories, and each column thereafter shows the number of significant associations observed for each of the disorders after multiple testing correction ($p < 2.23 \times 10^{-5}$).

<figure><img src="image_7.png" /><figcaption>**Fig. 5** Phenotypes significantly associated with TS PRS in either males or females; asterisk (*) indicates significant after multiple testing correction. The x-axis shows the Beta (effect size) of association between the phenotype and the genetic risk of TS in females and males. DD Disease Diagnosis, HMH Health and Medical History, SD Socio-demographics.</figcaption></figure>

Although we identified strong associations with multiple traits using a PheWAS approach, there are certain limitations of this study. We used a large dataset of over 300,000 samples but there were only about 30 individuals with tics and stuttering and no individual with TS diagnosis (defined by ICD-10 diagnoses) even though the expected number would have been around 1800 (0.6%) based on the prevalence of the condition. This could be because individuals with psychiatric conditions are less likely to participate in such studies and more likely to drop out during an ongoing study thus leading to a selection bias in the dataset [40]. Given the lack of TS cases, we could not calculate the exact predictive power of the TS PRS scores in the UKB dataset, which could have validated how well the PRS captured the differences between TS patients and controls. Additionally, due to reduced

overlap among the base and target datasets, the number of SNPs used for PRS calculation was lower for TS compared to the other neurodevelopmental disorders we studied here. This could possibly explain the low levels of correlation between TS PRS and the PRS of the other three disorders. We observe a higher number of associations for ADHD and ASD compared to TS and OCD, which could be attributed to the differences in the sample size of the discovery GWAS used for PRS calculation of these disorders [11, 25–27]. Finally, our observed associations do not provide information about causality but should be followed up with additional study designs like mendelian randomization in appropriate datasets, or twin studies. We observed correlations with various social outcomes such as education and employment; but again, our results do not infer causality. Calculation of genetic
risk estimates based on large-scale and more precise GWAS data are likely to be more predictive and may identify more outcomes associated with the disorder.

In conclusion, we showed that genetic liability of TS is associated with various phenotypic outcomes, several of which are also shared across other neurodevelopmental disorders like ADHD, ASD, and OCD. Phenotype associations with TS also appeared to differ based on sex. Our results suggest that it is important to consider a broad range of mental health, general health, and even sociodemographic outcomes associated with TS and other neurodevelopmental disorders to shed light in the complex etiology and related pathways underlying these conditions.

## CODE AVAILABILITY

The code to calculate PRS scores using PRScs is available at https://github.com/getian107/PRScs and the code to run the PheWAS can be found at https://github.com/MRCIEU/PHESANT.

## REFERENCES

1. Robertson MM, Cavanna AE, Eapen V. Gilles de la Tourette syndrome and disruptive behavior disorders: prevalence, associations, and explanation of the relationships. J Neuropsychiatry Clin Neurosci. 2015;27:33–41.

2. Scharf JM, Miller LL, Gauvin CA, Alabiso J, Mathews CA, Ben-Shlomo Y. Population prevalence of Tourette syndrome: a systematic review and meta-analysis. Mov Disord. 2015;30:221–8.

3. Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, et al. Partitioning the heritability of Tourette syndrome and obsessive-compulsive disorder reveals differences in genetic architecture. PLoS Genet. 2013. https://doi.org/10.1371/JOURNAL.PGEN.1003864.

4. Hirschtritt ME, Lee PC, Pauls DL, Dion Y, Grados MA, Illmann C, et al. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry. 2015;72:325–33.

5. Mataix-Cols D, Isomura K, Pérez-Vigil A, Chang Z, Rück C, Johan Larsson K, et al. Familial risks of Tourette syndrome and chronic Tic disorders: a population-based Cohort study. JAMA Psychiatry. 2015;72:787–93.

6. Yu D, Sul JH, Tsetsos F, Nawaz MS, Huang AY, Zelaya I, et al. Interrogating the genetic determinants of Tourette's syndrome and other Tic disorders through genome-wide association studies. American Journal of Psychiatry. 2019;176:217–27.

7. Paschou P, Yu D, Gerber G, Evans P, Tsetsos F, Davis LK, et al. Genetic association signal near NTN4 in Tourette syndrome. Ann Neurol. 2014;76:310–5.

8. Tsetsos F, Yu D, Sul JH, Huang AY, Illmann C, Osiecki L, et al. Synaptic processes and immune-related pathways implicated in Tourette syndrome. Translational Psychiatry 2021 11:1. 2021;11:1–12.

9. Levy AM, Paschou P, Tümer Z. Candidate genes and pathways associated with Gilles de la Tourette syndrome-where are we? Genes (Basel). 2021. https://doi.org/10.3390/GENES12091321.

10. Paschou P, Jin Y, Müller-Vahl K, Möller HE, Rizzo R, Hoekstra PJ, et al. Enhancing neuroimaging genetics through meta-analysis for Tourette syndrome (ENIGMA-TS): A worldwide platform for collaboration. Front Psychiatry. 2022;0:1763.

11. Tsetsos F, Topaloudi A, Jain P, Yang Z, Yu D, Kolovos P, et al. Genome-wide association study identifies two novel loci for Gilles de la Tourette syndrome. medRxiv. 2021;17:2021.12.11.21267560.

12. Brander G, Isomura K, Chang Z, Kuja-Halkola R, Almqvist C, Larsson H, et al. Association of Tourette syndrome and chronic tic disorder with metabolic and cardiovascular disorders. JAMA Neurol. 2019;76:454–61.

13. Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies. J Psychosom Res. 2008;65:461–72.

14. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009. https://doi.org/10.1038/nature08185.

15. Huang JY, Labrecque JA. From GWAS to PheWAS: the search for causality in big data. Lancet Digit Health. 2019;1:e101–3.

16. Fritsche LG, Gruber SB, Wu Z, Schmidt EM, Zawistowski M, Moser SE, et al. Association of Polygenic Risk Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan Genomics Initiative. The American Journal of Human Genetics. 2018;102:1048–61.

17. Joo YY, Actkins K, Pacheco JA, Basile AO, Carroll R, Crosslin DR, et al. A polygenic and phenotypic risk prediction for polycystic ovary syndrome evaluated by phenomewide association studies. J Clin Endocrinol Metabol. 2020. https://doi.org/10.1210/clinin/dgz326.

18. Leppert B, Millard LAC, Riglin L, Davey Smith G, Thapar A, Tilling K, et al. A cross-disorder PRS-pheWAS of 5 major psychiatric disorders in UK Biobank. PLoS Genet. 2020;16:e1008185.

19. Fu M, Group UPHDDRW, Group UPHAW, Chang TS, Antonio AL, Ariannejad M, et al. Phenome-wide association study of polygenic risk score for Alzheimer's disease in electronic health records. Front Aging Neurosci. 2022;0:142.

20. Yang Z, Wu H, Lee PH, Tsetsos F, Davis LK, Yu D, et al. Investigating shared genetic basis across Tourette syndrome and comorbid neurodevelopmental disorders along the impulsivity-compulsivity spectrum. Biol Psychiatry. 2021;90:317–27.

21. Lee PH, Anttila V, Won H, Feng YCA, Rosenthal J, Zhu Z, et al. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell. 2019;179:1469–82.e11.

22. Shen X, Howard DM, Adams MJ, David Hill W, Clarke T-K. Depressive M, et al. A phenome-wide association and Mendelian randomisation study of polygenic risk for depression in UK Biobank. Nat Commun. 2020. https://doi.org/10.1038/s41467-020-16022-0.

23. Bose A, Kalantzis V, Kontopoulou EM, Elkady M, Paschou P, Drineas P. TeraPCA: a fast and scalable software package to study genetic variation in tera-scale genotypes. Bioinformatics. 2019;35:3679–83.

24. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019. https://doi.org/10.1038/s41467-019-09718-5.

25. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51:431–44.

26. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019;51:63–75.

27. Arnold PD, Askland KD, Barlassina C, Bellodi L, Bienvenu OJ, Black D, et al. Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. Molecular Psychiatry. 2017;23:1181–8.

28. Millard LAC, Davies NM, Gaunt TR, Smith GD, Tilling K. Software Application Profile: PHESANT: a tool for performing automated phenome scans in UK Biobank. Int J Epidemiol. 2018;47:29–35.

29. Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, et al. Mapping ICD-10 and ICD-10-CM codes to phetaeces: workflow development and initial evaluation. JMIR Med Inform. 2019;7:e14325.

30. Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, et al. Analysis of shared heritability in common disorders of the brain. Science (1979). 2018;360:6395.

31. Piedad JCP, Cavanna AE. Depression in Tourette syndrome: a controlled and comparison study. J Neurol Sci. 2016;364:128–32.

32. Pérez-Vigil A, de La Cruz LF, Brander G, Isomura K, Jangmo A, Kuja-Halkola R, et al. Association of Tourette syndrome and chronic Tic disorders with objective indicators of educational attainment: a population-based sibling comparison study. JAMA Neurol. 2018;75:1098–105.

33. Lavenstein B, Miyares L, Dodge L. Pain in childhood Tourette syndrome-retrospective analysis (P3.267). Neurology. 2016;86:16.

34. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018. https://doi.org/10.1038/s41588-018-0090-3.

35. Flory K, Molina BSG, Pelham WE, Gnagy E, Smith B. Childhood ADHD Predicts Risky Sexual Behavior in Young Adulthood. 2010;35:571–7. https://doi.org/10.1207/s15374424jccp3504_8.

36. Garris J, Quigg M. The female Tourette patient: sex differences in Tourette disorder. Neurosci Biobehav Rev. 2021;129:261–8.

37. Garcia-Delgar B, Servera M, Coffey BJ, Lázaro L, Openneer T, Benaroya-Milshtein N, et al. Tic disorders in children and adolescents: does the clinical presentation differ in males and females? A report by the EMTICS group. Eur Child Adolesc Psychiatry. 2021. https://doi.org/10.1007/S00787-021-01751-4.

38. Baizabal-Carvallo JF, Jankovic J. Sex differences in patients with Tourette syndrome. CNS Spectr 2022. https://doi.org/10.1017/S1092852922000074.

39. Pagliaroli L, Veto B, Arányi T, Barta C. From genetics to epigenetics: new perspectives in Tourette syndrome research. Front Neurosci. 2016;10:277.

40. Taylor AE, Jones HJ, Sallis H, Euesden J, Stergiakouli E, Davies NM, et al. Exploring the association of genetic factors with participation in the Avon longitudinal study of parents and children. Int J Epidemiol. 2018;47:1207–16.

## AUTHOR CONTRIBUTIONS

PJ, PP, TM-F, and LKD designed the study, and performed primary analysis. All authors provided data, materials, and methods. All authors contributed to interpreting results, writing, reviewing, and editing the manuscript.
## FUNDING

This work was funded by NIH grants R01NS105746, R01MH126213, NSF grants 1715202, and 2006929, EMTICS (FP7-HEALTH, Grant agreement ID: 278367), and TS-EUROTRAIN (FP7-PEOPLE, Grant agreement ID: 316978) to P. Paschou. Z. Tumer was supported by Lundbeck Foundation (R100-A9332). C. Depienne was funded by the Deutsche Forschungsgemeinschaft. D.I. Boomsma was supported by KNAW Academy Professor Award (PAH/6635). P. Janik and C. Zekanowski were funded by the National Science Center, Poland: UMO-2016/23/B/NZ2/03030. D. Grice was supported by NIH grant R01MH124679. B. Hengerer is an employee of Boehringer Ingelheim Pharma. A. Schrag received support from the NIHR UCL/H Biomedical Research Centre. C. Mathews was supported by NIH grants (R01NS105746; R01NS102371).

## COMPETING INTERESTS

The authors declare no competing interests.

## ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at https://doi.org/10.1038/s41398-023-02341-5.

**Correspondence** and requests for materials should be addressed to Lea K. Davis or Peristera Paschou.

**Reprints and permission information** is available at http://www.nature.com/reprints

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_8.png" /></figure>

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023

## THE PSYCHIATRIC GENOMICS CONSORTIUM TOURETTE SYNDROME WORKING GROUP (PGC-TS)

Thomas D. Als, Harald Aschauer, Gil Atzmon, Matie Bækvad-Hansen, Csaba Barta²⁸, Cathy L. Barr, Nir Barzilai, James R. Batterson, Robert Batterson, Fortu Benarroch, Cheston Berlin, Julia Boberg, Benjamin Bodmer, Julia Bohnenpoll, Anders D. Børglum, Lawrence W. Brown, Ruth Bruun, Cathy L. Budman, Randy L. Buckner, Joseph D. Buxbaum³⁰,³¹,³²,³³,³⁴,³⁵, Jonas Bybjerg-Grauholm, Danielle C. Cath²⁰, Keun-Ah Cheon, Sylvain Chouinard, Barbara J. Coffey, Giovanni Coppola, James J. Crowley, Niklas Dahl, Lea K. Davis²,³, Sabrina M. Darrow, Mark J. Daly, Christel Depienne¹⁵, Silvia De Rubeis, Andrea Dietrich⁵⁷, Yves Dion, Diana R. Djurfeldt,

<footnote n="1">¹Department of Biological Sciences, Purdue University, West Lafayette, IN, USA. ²Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center Nashville, Nashville, TN, USA. ³Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. ⁴Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. ⁵Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁶Department of Computer Science, Purdue University, West Lafayette, IN, USA. ⁷Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece. ⁸¹st Laboratory of Medical Biology-Genetics, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. ⁹Child and Adolescent Neurology and Psychiatry, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. ¹⁰Department of Psychiatry, Social psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany. ¹¹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ¹²Department of Clinical Genetics, Kennedy Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. ¹³Department of Pediatrics, Herlev University Hospital, Herlev, Denmark. ¹⁴Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France. ¹⁵Institute for Human Genetics, University Hospital Essen, Essen, Germany. ¹⁶Assistance Publique Hôpitaux de Paris, Sorbonne University, Faculty of Medicine Hopital Saint Antoine, Paris, France. ¹⁷French Reference Centre for Gilles de la Tourette Syndrome, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. ¹⁸Unidad de Trastornos del Movimiento. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain. ¹⁹Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. ²⁰Department of Clinical and health Psychology, Utrecht University, Utrecht, Netherlands. ²¹Institute for Anatomy and Cell Biology, Ulm University, Ulm, Germany. ²²EMGO+Institute for Health and Care Research, VU University Medical Centre, Amsterdam, Netherlands. ²³Department of Child and Adolescent Psychiatry, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany. ²⁴Department of Child Psychiatry, Medical University of Warsaw, Warsaw, Poland. ²⁵Department of Neurology, Medical University of Warsaw, Warsaw, Poland. ²⁶Department of Bioethics, Medical University of Warsaw, Warsaw, Poland. ²⁷Department of Neurogenetics and Functional Genomics, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland. ²⁸Department of Molecular Biology, Institute of Biochemistry and Molecular Biology, Semmelweis University, Budapest, Hungary. ²⁹Vadaskert Clinic for Child and Adolescent Psychiatry, Budapest, Hungary. ³⁰Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA. ³¹Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, USA. ³²Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA. ³³Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, USA. ³⁴The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, USA. ³⁵Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, USA. ³⁶Division of Tics, OCD, and Related Disorders, Icahn School of Medicine at Mount Sinai, New York, USA. ³⁷Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, New York, Netherlands. ³⁸deCODE Genetics/Amgen, Reykjavik, Iceland. ³⁹Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Research, Boehringer, Germany. ⁴⁰Child and Adolescent Psychiatry Department, Schneider Children's Medical Centre of Israel, Petah-Tikva. Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ⁴¹Department of Human Neurosciences, University La Sapienza of Rome, Rome, Italy. ⁴²Evelina London Children's Hospital GSTT, Kings Health Partners AHSC, London, UK. ⁴³Psychological Medicine, Great Ormond Street Hospital NHS Foundation Trust, Great Ormond Street, London, UK. ⁴⁴Levvel, Academic Center for Child and Adolescent Psychiatry, Amsterdam, The Netherlands. ⁴⁵Amsterdam UMC, Department of Child and Adolescent Psychiatry, Amsterdam, The Netherlands. ⁴⁶Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic Universitario, Barcelona, Spain. ⁴⁷Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. ⁴⁸Centro de Investigacion en Red de Salud Mental (CIBERSAM), Instituto Carlos III, Barcelona, Spain. ⁴⁹Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany. ⁵⁰Institute of Systems Motor Science, University of Lübeck, Lübeck, Germany. ⁵¹Child and Adolescent Mental Health Centre, Mental Health Services, Capital Region of Denmark and University of Copenhagen, Copenhagen, Denmark. ⁵²Division of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland. ⁵³ASL BA, Maternal and Childood Department, Adolescence and Childhood Neuropsychiatry Unit, Bari, Italy. ⁵⁴Department of Child and Adolescent Psychiatry and Psychotherapy, University of Zurich, Zurich, Switzerland. ⁵⁵Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, University College London, London, UK. ⁵⁶Department of Clinical Neurosciences, Cumming School of Medicine & Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada. ⁵⁷University of Groningen, University Medical Center Groningen, Department of Child and Adolescent Psychiatry, Groningen, the Netherlands. ⁵⁸Department of Psychiatry and Genetics Institute, University of Florida College of Medicine, Florida, USA. ⁵⁹Department of Neurology, Brigham and Women's Hospital, and the Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. *A list of authors and their affiliations appears at the end of the paper. ⁵⁹email: lea.k.davis@vumc.org; ppaschou@purdue.edu</footnote>
Laura Domenech-Salgado, Valsamma Eapen, Lonneke Elzerman, Thomas V. Fernandez, Nelson B. Freimer Carolin Fremer, Blanca Garcia-Delgar, Marcos Garrido, Donald L. Gilbert, Paola Giusti-Rodriguez, Marco Grados, Erica Greenberg, Jakob Grove, Dorothy E. Grice³⁰,³⁴,³⁵,³⁶, Julie Hagstrom, Matt Halvorsen, Andreas Hartmann¹⁴, Bjarne Hansen, Jan Haavik, Johannes Hebebrand, Gary A. Heiman, Luis Herrera, Isobel Heyman⁴³, Anke Hinney, Matthew E. Hirschtritt, Pieter J. Hoekstra⁵⁷, Jae Hoon Sul, Hyun Ju Hong, David M. Hougaard, Alden Y. Huang, Laura Ibanez-Gomez, Franjo Ivankovic, Joseph Jankovic, Elinor K. Karlsson, Jakko A. Kaprio, Young Key Kim, Young-Shin Kim, Robert A. King, James A. Knowles, Yun-Joo Koh, Sodham Kook, Najah Khalifa, Anastasios Konstantinidis, Samuel Kuperman, Roger Kurlan, Gerd Kvale, James Leckman, Paul C. Lee, Bennett Leventhal, Paul Lichtenstein, Kerstin Lindbald-Toh, Thomas Lowe, Andrea Ludolph, Claudia Luhrs da Silva, Pétur Luðvigsson, Jurjen Luykx, Gholson J. Lyon, Behrang Mahjani, Athanasios Maras, David Mataix-Cols, Manuel Mattheisen, Carol A. Mathews⁵⁸, Irene A. Malaty, William M. McMahon, Andrew McQuillin, Sandra M. Meier, Tyne Miller-Fleming²,³, Pablo Mir¹⁸,¹⁹, Rainald Moessner, Astrid Morer⁴⁶,⁴⁷,⁴⁸, Preben B. Mortensen, Ole Mors, Poorva Mudgal, Kirsten R. Muller-Vahl¹⁰, Alexander Munchau⁵⁰, Peter Nagy, Allan Naarden, Benjamin M. Neale, Muhammad S. Nawaz, Judith Becker Nissen, Markus M. Nöthen Merete Nordentoft, Ashley E. Nordsletten, Michael S. Okun, Roel Ophoff, Lisa Osiecki, Aarno Palotie, Teemu P. Palviainen, Peristera Paschou¹, Carlos N. Pato Michele T. Pato, Christopher Pittenger, Kerstin J. Plessen⁵¹,⁵², Yehuda Pollak, Danielle Posthuma, Eliana Ramos, Jennifer Reichert, Renata Rizzo⁹, Mary M. Robertson, Veit Roessner²³, Joshua L. Roffman, Guy Rouleau, Christian Rück, Evald Sæmundsen, Jack Samuels, Sven Sandin, Paul Sandor, Monika Schlögelhofer, Jeremiah M. Scharf⁴,⁵,⁵⁹, Eun-Young Shin, Harvey S. Singer, Jan Smit, Jordan W. Smoller, Matthew State, Stian Solem, Dong-Ho Song, Jungeun Song, Mara Stamenkovic, Hreinn Stefansson³⁸, Kári Stefansson, Nora Strom, Manfred Stuhrmann, Jin Szatkiewicz, Urszula Szymanska, Zsanett Tarnok³⁰, Jay A. Tischfield, Fotis Tsetsos, Ólafur Thorarensen, Jennifer Tubing, Frank Visscher, Michael Wagner, Sina Wanderer, Sheng Wang, Thomas Werge, Jeremy A. Willsey, Tomasz Wolancyk²⁴, Douglas W. Woods, Martin Woods, Yulia Worbe¹⁶,¹⁷, Yves Dion, Dongmei Yu⁴,⁵, Ivette Zelaya and Samuel H. Zinner

## THE EMTICS COLLABORATIVE GROUP

Alan Apter, Juliane Ball, Benjamin Bodmer, Emese Bognar, Judith Buse, Marta Correa Vela, Carolin Fremer, Blanca Garcia-Delgar, Mariangela Gulisano, Annelieke Hagen, Julie Hagstrøm, Marcos Madruga-Garrido, Peter Nagy, Alessandra Pellico, Daphna Ruhrman, Jaana Schnell, Paola Rosaria Silvestri, Liselotte Skov, Tamar Steinberg, Friederike Tagwerker Gloor, Victoria L. Turner, Elif Weidinger, Noa Benaroya-Milshtein⁴⁰, Francesco Cardona⁴¹, Andrea Dietrich⁵⁷, Marianthi Georgitsi⁷,⁸, Tammy Hedderly ¹⁰,²⁸, Isobel Heyman⁴³, Pieter J. Hoekstra⁵⁷, Chaim Huyser ⁴⁴,⁴⁵, Davide Martino⁵⁶, Pablo Mir ¹⁸,¹⁹, Astrid Morer⁴⁶,⁴⁷,⁴⁸, Kirsten R. Muller-Vahl¹⁰, Peristera Paschou¹, Kerstin J. Plessen⁵¹,⁵², Cesare Porcelli⁵³, Renata Rizzo⁹, Veit Roessner ²³, Anette Schrag⁵⁵ and Zsanett Tarnok ²⁹

## THE TS-EUROTRAIN NETWORK

John Alexander, Tamas Aranyi, Wim R. Buisman, Jan K. Buitelaar, Nicole Driessen, Petros Drineas⁶, Siyan Fan, Natalie J. Forde, Sarah Gerasch, Odile A. van den Heuvel, Cathrine Jespersgaard, Ahmad S. Kanaan, Harald E. Möller, Muhammad S. Nawaz, Ester Nespoli, Luca Pagliaroli, Geert Poelmans, Petra J. W. Pouwels, Francesca Rizzo, Dick J. Veltman, Ysbrand D. van der Werf, Joanna Widomska, Nuno R. Zilhão, Csaba Barta ²⁸, Dorret I. Boomsma ²¹,²², Danielle C. Cath²⁰, Marianthi Georgitsi⁷,⁸, Jeffrey Glennon³⁷, Bastian Hengerer ³⁹, Pieter J. Hoekstra⁵⁷, Kirsten R. Muller-Vahl¹⁰, Peristera Paschou¹, Hreinn Stefansson³⁸ and Zeynep Tumer ¹¹,¹²